Cargando…

A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease

BACKGROUND: Parkinson’s disease (PD) is a progressive neurodegenerative condition that primarily affects motor functions; it is caused by the loss of midbrain dopaminergic (mDA) neurons. The therapeutic effects of transplanting human-induced pluripotent stem cell (iPSC)-derived mDA neural progenitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Ryota, Nonaka, Risa, Oyama, Genko, Jo, Takayuki, Kamo, Hikaru, Nuermaimaiti, Maierdanjiang, Akamatsu, Wado, Ishikawa, Kei-ichi, Hattori, Nobutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368972/
https://www.ncbi.nlm.nih.gov/pubmed/37502682
http://dx.doi.org/10.3389/fnins.2023.1202027
_version_ 1785077642837360640
author Nakamura, Ryota
Nonaka, Risa
Oyama, Genko
Jo, Takayuki
Kamo, Hikaru
Nuermaimaiti, Maierdanjiang
Akamatsu, Wado
Ishikawa, Kei-ichi
Hattori, Nobutaka
author_facet Nakamura, Ryota
Nonaka, Risa
Oyama, Genko
Jo, Takayuki
Kamo, Hikaru
Nuermaimaiti, Maierdanjiang
Akamatsu, Wado
Ishikawa, Kei-ichi
Hattori, Nobutaka
author_sort Nakamura, Ryota
collection PubMed
description BACKGROUND: Parkinson’s disease (PD) is a progressive neurodegenerative condition that primarily affects motor functions; it is caused by the loss of midbrain dopaminergic (mDA) neurons. The therapeutic effects of transplanting human-induced pluripotent stem cell (iPSC)-derived mDA neural progenitor cells in animal PD models are known and are being evaluated in an ongoing clinical trial. However, However, improvements in the safety and efficiency of differentiation-inducing methods are crucial for providing a larger scale of cell therapy studies. This study aimed to investigate the usefulness of dopaminergic progenitor cells derived from human iPSCs by our previously reported method, which promotes differentiation and neuronal maturation by treating iPSCs with three inhibitors at the start of induction. METHODS: Healthy subject-derived iPS cells were induced into mDA progenitor cells by the CTraS-mediated method we previously reported, and their proprieties and dopaminergic differentiation efficiency were examined in vitro. Then, the induced mDA progenitors were transplanted into 6-hydroxydopamine-lesioned PD model mice, and their efficacy in improving motor function, cell viability, and differentiation ability in vivo was evaluated for 16 weeks. RESULTS: Approximately ≥80% of cells induced by this method without sorting expressed mDA progenitor markers and differentiated primarily into A9 dopaminergic neurons in vitro. After transplantation in 6-hydroxydopamine-lesioned PD model mice, more than 90% of the engrafted cells differentiated into the lineage of mDA neurons, and approximately 15% developed into mature mDA neurons without tumour formation. The grafted PD model mice also demonstrated significantly improved motor functions. CONCLUSION: This study suggests that the differentiation protocol for the preparation of mDA progenitors is a promising option for cell therapy in patients with PD.
format Online
Article
Text
id pubmed-10368972
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103689722023-07-27 A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease Nakamura, Ryota Nonaka, Risa Oyama, Genko Jo, Takayuki Kamo, Hikaru Nuermaimaiti, Maierdanjiang Akamatsu, Wado Ishikawa, Kei-ichi Hattori, Nobutaka Front Neurosci Neuroscience BACKGROUND: Parkinson’s disease (PD) is a progressive neurodegenerative condition that primarily affects motor functions; it is caused by the loss of midbrain dopaminergic (mDA) neurons. The therapeutic effects of transplanting human-induced pluripotent stem cell (iPSC)-derived mDA neural progenitor cells in animal PD models are known and are being evaluated in an ongoing clinical trial. However, However, improvements in the safety and efficiency of differentiation-inducing methods are crucial for providing a larger scale of cell therapy studies. This study aimed to investigate the usefulness of dopaminergic progenitor cells derived from human iPSCs by our previously reported method, which promotes differentiation and neuronal maturation by treating iPSCs with three inhibitors at the start of induction. METHODS: Healthy subject-derived iPS cells were induced into mDA progenitor cells by the CTraS-mediated method we previously reported, and their proprieties and dopaminergic differentiation efficiency were examined in vitro. Then, the induced mDA progenitors were transplanted into 6-hydroxydopamine-lesioned PD model mice, and their efficacy in improving motor function, cell viability, and differentiation ability in vivo was evaluated for 16 weeks. RESULTS: Approximately ≥80% of cells induced by this method without sorting expressed mDA progenitor markers and differentiated primarily into A9 dopaminergic neurons in vitro. After transplantation in 6-hydroxydopamine-lesioned PD model mice, more than 90% of the engrafted cells differentiated into the lineage of mDA neurons, and approximately 15% developed into mature mDA neurons without tumour formation. The grafted PD model mice also demonstrated significantly improved motor functions. CONCLUSION: This study suggests that the differentiation protocol for the preparation of mDA progenitors is a promising option for cell therapy in patients with PD. Frontiers Media S.A. 2023-07-12 /pmc/articles/PMC10368972/ /pubmed/37502682 http://dx.doi.org/10.3389/fnins.2023.1202027 Text en Copyright © 2023 Nakamura, Nonaka, Oyama, Jo, Kamo, Nuermaimaiti, Akamatsu, Ishikawa and Hattori. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Nakamura, Ryota
Nonaka, Risa
Oyama, Genko
Jo, Takayuki
Kamo, Hikaru
Nuermaimaiti, Maierdanjiang
Akamatsu, Wado
Ishikawa, Kei-ichi
Hattori, Nobutaka
A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease
title A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease
title_full A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease
title_fullStr A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease
title_full_unstemmed A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease
title_short A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson’s disease
title_sort defined method for differentiating human ipscs into midbrain dopaminergic progenitors that safely restore motor deficits in parkinson’s disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368972/
https://www.ncbi.nlm.nih.gov/pubmed/37502682
http://dx.doi.org/10.3389/fnins.2023.1202027
work_keys_str_mv AT nakamuraryota adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT nonakarisa adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT oyamagenko adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT jotakayuki adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT kamohikaru adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT nuermaimaitimaierdanjiang adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT akamatsuwado adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT ishikawakeiichi adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT hattorinobutaka adefinedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT nakamuraryota definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT nonakarisa definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT oyamagenko definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT jotakayuki definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT kamohikaru definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT nuermaimaitimaierdanjiang definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT akamatsuwado definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT ishikawakeiichi definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease
AT hattorinobutaka definedmethodfordifferentiatinghumanipscsintomidbraindopaminergicprogenitorsthatsafelyrestoremotordeficitsinparkinsonsdisease